Synergy Pharmaceuticals Inc

Synergy Pharmaceuticals — Investor Presentation (August 2010)

33 slides from Synergy Pharmaceuticals's investor presentation, Aug 10, 2010

  1. Slide 1: Developing new Treatments for GI Disorders and Diseases

    Developing new Treatments for GI Disorders and Diseases Gary S. Jacob, Ph.D. President & CEO August 13, 2010

  2. Slide 2: Forward-Looking Information

    Certain statements made in this presentation are forward-looking. Such statements are indicated by words such as “expect,” “should,” “anticipate” and similar words indicating uncertainty in facts and figures. Although Synergy believes that the expectations reflected in such forward-looking statement

  3. Slide 3: Overview

    OVERVIEW Symbol & Exchange: SGYP (OTCBB) www.synergypharma.com Proprietary Technology – GC-C Receptor Agonists Lead Drug – Plecanatide (SP-304) in Phase II trial to treat GI Disorders Experienced Management Team Headquartered in New York, NY; Research lab in Doylestown, PA More than $23 million rais

  4. Slide 4: Synergy Pharmaceuticals – Key Points

    Introduction to Synergy Pharmaceuticals Synergy Pharmaceuticals – Key Points Technology Proprietary technology, not in-licensed Command 100% of commercial rights worldwide Major potential to treat GI disorders & diseases Platform potential to cover additional diseases Application Plecanatide (SP-304

  5. Slide 5: Synergy Pharmaceuticals – Key Points (Cont.)

    Introduction to Synergy Pharmaceuticals Synergy Pharmaceuticals – Key Points (Cont.) Strong IP position Issued U.S. comp-of-matter patent on plecanatide, protection to 2024. Broad IP estate Opportunity Validated target for GI disorders with potential for “Best-in-Class” drug Low Risk Plecanatide ben

  6. Slide 6: GI Disorders & Diseases Significant Market Opportunity

    GI Disorders & Diseases Significant Market Opportunity

  7. Slide 7: Significant Unmet Medical Need

    Significant Unmet Medical Need Hard and lumpy stools, straining during defecation, a sensation of incomplete evacuation, and fewer than three bowel movements per week Significantly affects patients’ quality of life by impairing their ability to work and participate in typical daily activities Limite

  8. Slide 8: The Market for a GI-Disorder Drug

    The Market for a GI-Disorder Drug 35 million to 46 million people in U.S. suffer from CC and IBS-C >100 million people worldwide Severe condition: 20 million in US, Europe & Japan High prevalence: approx. 15% of U.S. population suffer from CC Estimate 6 million to 8.5 million patients in U.S. with C

  9. Slide 9: Major “Game-Changing” Events

    Major “Game–Changing” Events: Marketed by Novartis 5-HT4 agonist withdrawn from market in spring 2007 due to cardio-toxicity $560 M sales in 2006, worldwide 32% growth, year on year Approved for chronic constipation and IBS-C Major impact on all future 5-HT4 agonist candidates Highlights need for ne

  10. Slide 10: Competitive Landscape

    Competitive Landscape Amitiza® (lubiprostone) Marketed by Sucampo/Takeda Chloride C-2 channel activator Approved for CC in 2006; IBS-C in 2008 $200 million annual sales in 2008 Main side effect is nausea Approx. 30% of patients Sets high price for market ~$3.80 / day retail -$3.35 / day ex-factory S

  11. Slide 11: Linaclotide First-in-Class GC-C Agonist

    Linaclotide First-in-Class GC-C Agonist Co-developed by Ironwood/Forest Laboratories First-in-class GC-C receptor agonist Developed for both CC and IBS-C Currently finishing Phase III IBS-C registration trials Projected NDA filing – middle of 2011* Potential launch in 2012* *Source: Ironwood 2Q2010

  12. Slide 12: GC-C Receptor Agonists

    GC-C Receptor Agonists

  13. Slide 13: Guanylate Cyclase C (GC-C) Receptors

    Guanylate Cyclase C (GC-C) Receptors Physiological mechanism Guanylate Cyclase C (GC-C) receptors are present on lumenal side of gut Key regulator of salt and liquid content of gut The CFTR when activated secretes Cl- and HCO3- into intestinal lumen, along with fluid Cross section of the GI tract

  14. Slide 14: Plecanatide (SP-304): Mechanism-of-Action

    Plecanatide (SP-304): Mechanism-of-Action Activation of Cl- Channels promotes Fluid Secretion into Lumen Plecanatide

  15. Slide 15: Our Lead Drug: Plecanatide (SP-304)

    Our Lead Drug: Plecanatide (SP-304) 16-mer analog of natural uroguanylin Single key amino acid change Locked into stable active conformer Compact stable molecule Thermo and acid stable (100 °C, pH 2) High resistance to proteases Behaves like a small molecule drug More potent than the natural hormone

  16. Slide 16: Only Two GC-C Agonists in Clinical Development

    ST-peptide Produced by E. coli Bacteria Uroguanylin Natural Hormone Linaclotide: ST-peptide Analog NDECELCVNVACTGCL Plecanatide: Uroguanylin Analog Only Two GC-C Agonists Currently in Clinical Development for CC and IBS NSSNYCCELCCNPACTGCY CCEYCCNPACTGCY NDDCELCVNVACTGCL Single letters denote differ

  17. Slide 17: Rationale for Plecanatide as Potential Best-in-Class Drug

    Rationale for Plecanatide as Potential Best-in-Class Drug Modulates binding constant with mucosal acidity NDECELCVNVACTGCL Plecanatide: Uroguanylin Analog Defines agonist activity Single letters denote different amino acids Colored lines denote disulphide bonds

  18. Slide 18: Plecanatide Clinical Development

    Plecanatide Clinical Development

  19. Slide 19: Plecanatide Phase I Trial in Volunteers

    Plecanatide Phase I Trial in Volunteers Protocol No. SP-SP304101-08 “Single-site, Randomized, Double-blind, Placebo-Controlled, Single-, Ascending-, Oral-Dose Safety, Tolerability, and Pharmacokinetic Study of Plecanatide in Healthy Adult Human Male and Female Volunteers“ Cohorts administered a sing

  20. Slide 20: Study Summary

    Study Summary No systemic absorption of plecanatide observed at all administered doses PK collected through 48 hours post-dose Plecanatide was well-tolerated Did not reach an MTD No serious adverse events reported Minimal AEs reported

  21. Slide 21: Plecanatide Clinical Plan & Timeline

    Plecanatide Clinical Plan & Timeline Extensive plecanatide manufacture scale-up underway Plecanatide formulation presently underway March 18, 2010 Began Phase IIa 14-day CC trial Initiate Phase IIb 28-day, fixed dose 28-day CC clinical trial Clinical data presently being evaluated to set doses for 2

  22. Slide 22: Plecanatide Phase IIb Clinical Plans & Timeline

    Plecanatide Phase IIb Clinical Plans & Timeline Initiate Phase IIb 28-day, fixed dose 28-day CC clinical trial Aug. 2010 Dec. 2010 June 2011 Initiate Phase IIb 90-day, fixed dose IBS-C clinical trial

  23. Slide 23: Plecanatide Phase IIb Trials in CC and IBS-C

    Plecanatide Phase IIb Trials in CC and IBS-C Next two trials: Phase IIb 28-day multiple-dose, placebo-controlled trial in CC patients (N~320) Trial powered for statistical significance Phase IIb 12-week multiple-dose, placebo-controlled trial in IBS-C (N~600) multiple-dose study utilizing fixed dose

  24. Slide 24: GC-C Receptor Agonists have an Established Valuation

    GC-C Receptor Agonists have an Established Valuation Partnership deal announced between Ironwood and Forest Laboratories for North American rights to linaclotide Forest paid $70 M upfront and $260 M in near term milestones for 50/50 rights to US, plus Canada and Mexico September 2007 May 2009 Almira

  25. Slide 25: Further Validation of GI Disorder Drugs

    Further Validation of GI Disorder Drugs Shire (UK: SHP) offers 428 million euros ($566 million) in cash deal for Belgian specialty GI company Movetis (BE:Move) with recently approved drug Resolor for CC (*estimated potential peak sales of over EUR300 million) August 2010 Source: Shire press release

  26. Slide 26: Platform Technology SP-333

    Platform Technology SP-333

  27. Slide 27: GC-C Receptor Agonist Program is a Technology Platform

    Synergy’s GC-C Receptor Agonist Program is a Technology Platform “Second-generation” drug positioned for ulcerative colitis (UC) GC-C agonists exhibit potent anti-inflammatory activity in animal models of inflammation Novel mechanism-of-action IND planned for 4Q2010 IP status – Key comp-of-matter pa

  28. Slide 28: Activation of GC-C Leads to GI Anti-inflammatory Activity

    Activation of GC-C Leads to GI Anti-inflammatory Activity Epithelial membrane cAMP AMP PKA PDE-III GTP PKG-II cGMP Na+ Ca+ Na+ Ca+ Cl- HCO3- HCO3- Cl- ClC2 CFTR CNG GC-C SP-304 SP-333 Anti-proliferative Anti-inflammatory Cl- HCO3- Na+/K+ homeostasis Amitiza® CIC & IBS IBD CANCER Intestinal lumen Dow

  29. Slide 29: GC-C Agonists Improve Histology in TNBS Mouse Model

    TNBS Balb/c mice treated with GC-C agonists show histological improvement and suppressed intestinal secretion of pro-inflammatory cytokines 0 40 80 120 IL-12 p40 IL-23 TNF Cytokines, pg/ml Control SP304, 50 ug/day 160 0 5 10 15 20 25 Histopathology Score SP-304 (ug/day) 0 10 20 50 n-9 n-8 n-4 n-5

  30. Slide 30: Initial Clinical Trial Planned for SP-333

    Initial Clinical Trial Planned for SP-333 Phase I single-dose, dose-escalation trial in healthy volunteers (N = 40) Safety, tolerability and PK of orally administered SP-333 Establish that SP-333 is not systemically absorbed in volunteers To be followed by evaluation in ulcerative colitis patients

  31. Slide 31: Future Synergy Value Creation Milestones

    Future Synergy Value Creation Milestones Mar. 18 Initiated plecanatide Phase IIa 14-day CC trial 3Q2010 * Report Phase 2a clinical data 4Q2010 * Initiate plecanatide Phase IIb 28-day CC trial 4Q2010 File IND on SP-333 1Q2011 Initiate SP-333 Phase I trial in healthy volunteers 2Q2011* Initiate plecan

  32. Slide 32: Synergy: Opportunity

    Synergy: Opportunity Plecanatide is less than 1 month away from completing Phase IIa proof of efficacy trial in chronic constipation Oral drugs for GI disorders & diseases Targeted therapy – specific selective receptor in GI tract Virtually no systemic absorption – low risk of toxicity Clinical proo

  33. Slide 33: Thank You

    THANK YOU

Synergy Pharmaceuticals — Investor Presentation (August 2010) on 6ix